Using KEGG pathway analysis, the targets of dapagliflozin involved in protecting DKD distributed in the fatty acid metabolism and degradation, carbohydrate digestion and absorption, and the PPAR signaling pathway. Here, PPARA is linked to diabetic kidney disease.